Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Assets: 2012-2024

Historic Assets for Ptc Therapeutics (PTCT) over the last 13 years, with Dec 2024 value amounting to $1.7 billion.

  • Ptc Therapeutics' Assets rose 43.50% to $2.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 billion, marking a year-over-year increase of 43.50%. This contributed to the annual value of $1.7 billion for FY2024, which is 10.06% down from last year.
  • Per Ptc Therapeutics' latest filing, its Assets stood at $1.7 billion for FY2024, which was down 10.06% from $1.9 billion recorded in FY2023.
  • Ptc Therapeutics' 5-year Assets high stood at $2.2 billion for FY2020, and its period low was $1.7 billion during FY2024.
  • Its 3-year average for Assets is $1.8 billion, with a median of $1.7 billion in 2022.
  • As far as peak fluctuations go, Ptc Therapeutics' Assets spiked by 36.00% in 2020, and later decreased by 12.24% in 2021.
  • Ptc Therapeutics' Assets (Yearly) stood at $2.2 billion in 2020, then fell by 12.24% to $1.9 billion in 2021, then decreased by 11.99% to $1.7 billion in 2022, then rose by 11.14% to $1.9 billion in 2023, then dropped by 10.06% to $1.7 billion in 2024.